Biomarker ID | 1350 |
PMID | 24565955 |
Year | 2014 |
Biomarker | N-telopeptides of type 1 collagen [NTx] |
Biomarker Basis | Concentration Based (nM) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | NA |
Odds Ratio/Hazard Ratio/Relative Risk | HR: 1.40 (95% CI: 1.27-1.54) |
Effect on Pathways | NA |
Experiment | Overall Survival Vs No Survival |
Type of Biomarker | Prognostic |
Cohort | 778 patients were randomly divided into two groups: Docetaxel/ atrasentan (n=382) and Docetaxel/placebo (n=396) |
Senstivity | NA |
Specificity | NA |
AUC | Atrasentan Arm: 0.66; Placebo Arm: 0.60 |
Accuracy | NA |
Level Of Significance | p <0.001 |
Method Used | ELISA |
Clinical | Yes |
Remarks | Estimates for the difference between arms (atrasentan – placebo) in the mean change in log2 bone marker concentrations (from baseline to week9), adjusted for bisphosphonate usage. |
Clinical Trial Number | NCT00134056 |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | NA |